{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:09:33Z","timestamp":1749010173537,"version":"3.41.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer Ltd.","doi-asserted-by":"crossref","award":["Pfizer Ltd."],"award-info":[{"award-number":["Pfizer Ltd."]}],"id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Sickle Cell Health Awareness, Perspectives and Experiences (SHAPE) Survey was previously developed for healthcare professionals, caregivers and patients from North America, Europe and Middle East. The current survey aims to broaden our understanding of the burden of Sickle Cell Disease (SCD), highlights the experiences of healthcare providers (HCPs) and identify unmet needs from Southeast Asia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The survey was a cross-sectional quantitative study conducted by Ipsos UK on behalf of Pfizer. It involved a 12-minute online survey with HCPs from India, Malaysia, and Thailand if they were managing\u2009\u2265\u20093 patients with SCD for &gt;\u20091 year. The survey covered aspects such as the impact of SCD on quality of life, treatment, and HCP knowledge and perceptions. The responses were collected either online or through face-to-face meetings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The survey link was accessed by 205 HCPs across the three countries. Of these, 105 (51.2%) HCPs were found to be eligible. A total of 85 (80.9%) HCPs completed the survey. Fatigue\/tiredness and vaso-occlusive crisis (VOCs) pain were the most commonly stated symptoms by the patients. HCPs believed that SCD impacts long-term health consequences, self-esteem, and mental health. Hydroxyurea was reported to be the most commonly used treatment. The Financial impact of SCD on patients was reported by 78% HCPs. More HCPs in India consider the cost\/benefit ratio to the patient and healthcare system before recommending a treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>There is a need for greater recognition of the financial burden and impact on overall wellbeing of patients and their families. Surveyed HCPs are optimistic about using novel treatment options but need additional support for educating patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03765-6","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:21:00Z","timestamp":1748938860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sickle cell health awareness, perspectives and experiences (SHAPE) survey: perspectives on sickle cell disease (SCD) from healthcare providers in India, Malaysia, and Thailand"],"prefix":"10.1186","volume":"20","author":[{"given":"Roy","family":"Gomez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabel","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"3765_CR1","unstructured":"What Is Sickle Cell Disease?. NIH; [cited 2024 4 January]. Available from: https:\/\/www.nhlbi.nih.gov\/health\/sickle-cell-disease"},{"issue":"8","key":"3765_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/ajh.23232","volume":"87","author":"MH Steinberg","year":"2012","unstructured":"Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol. 2012;87(8):795\u2013803.","journal-title":"Am J Hematol"},{"key":"3765_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/hemato3020024","volume":"3","author":"CK Tebbi","year":"2022","unstructured":"Tebbi CK. Sickle cell disease, a review. Hemato. 2022;3:341\u201366.","journal-title":"Hemato"},{"key":"3765_CR4","unstructured":"Sickle Cell Disease (SCD). What is Sickle Cell Disease? Centers for Disease Control and Prevention (CDC); [cited 2024 4 January]. Available from: https:\/\/www.cdc.gov\/sickle-cell\/about\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/facts.html"},{"key":"3765_CR5","unstructured":"Overview, Sickle Cell Disease: NHS UK; 2022 [cited 2024 16 January]. Available from: https:\/\/www.nhs.uk\/conditions\/sickle-cell-disease\/#:~:text=The%20main%20symptoms%20of%20sickle,tiredness%20and%20shortness%20of%20breath"},{"issue":"8","key":"3765_CR6","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","volume":"10","author":"GBDSCD Collaborators","year":"2023","unstructured":"Collaborators GBDSCD. Global, regional, and National prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the global burden of disease study 2021. Lancet Haematol. 2023;10(8):e585\u201399.","journal-title":"Lancet Haematol"},{"issue":"5","key":"3765_CR7","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/hpm.3674","volume":"38","author":"BV Babu","year":"2023","unstructured":"Babu BV, Sharma Y, Surti SB, Bhat D, Sridevi P, Ranjit M, et al. Indian sickle cell disease registry for surveillance and patient management: development and implementation. Int J Health Plann Manage. 2023;38(5):1483\u201394.","journal-title":"Int J Health Plann Manage"},{"issue":"3","key":"3765_CR8","first-page":"288","volume":"138","author":"S Tewari","year":"2013","unstructured":"Tewari S, Rees D. Morbidity pattern of sickle cell disease in India: a single centre perspective. Indian J Med Res. 2013;138(3):288\u201390.","journal-title":"Indian J Med Res"},{"key":"3765_CR9","doi-asserted-by":"crossref","unstructured":"Colombatti R, Hegemann I, Medici M, Birkegard C. Systematic literature review shows gaps in data on global prevalence and birth prevalence of sickle cell disease and sickle cell trait: call for action to scale up and harmonize data collection. J Clin Med. 2023;12(17).","DOI":"10.3390\/jcm12175538"},{"issue":"9861","key":"3765_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","volume":"381","author":"FB Piel","year":"2013","unstructured":"Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary Geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142\u201351.","journal-title":"Lancet"},{"key":"3765_CR11","doi-asserted-by":"crossref","unstructured":"Odame I, Anderson A, Costa F, Inusa B, Jastaniah W, Kunz J et al. O-10 sickle cell health awareness, perspectives and experiences (SHAPE) survey: findings on the burden of sickle cell disease and unmet needs as reported by patients and caregivers. The 4th Global Congress on Sickle Cell Disease: HemaSphere; 2022.","DOI":"10.1097\/01.HS9.0000928200.69096.c5"},{"key":"3765_CR12","doi-asserted-by":"crossref","unstructured":"de Montalembert M, Anderson A, Costa F, Jastaniah W, Kunz J, Odame I et al. P1487 Sickle Cell Health Awareness, Perspectives and Experiences (Shape) Survey: Findings on the Burden of Sickle Cell Disease on Patients and Their Unmet Needs as Reported by Healthcare Professionals. ASCAT-EHA-BSH Sickle Cell Disease Conference. 2022: HemaSphere; 2022.","DOI":"10.1097\/01.HS9.0000848804.55532.74"},{"issue":"1","key":"3765_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-021-01781-w","volume":"16","author":"T Darshana","year":"2021","unstructured":"Darshana T, Rees D, Premawardhena A. Hydroxyurea and blood transfusion therapy for sickle cell disease in South Asia: inconsistent treatment of a neglected disease. Orphanet J Rare Dis. 2021;16(1):148.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"3765_CR14","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/trstmh\/trac095","volume":"116","author":"P Sridevi","year":"2022","unstructured":"Sridevi P, Sharma Y, Balakrishna SL, Babu BV. Sickle cell disease treatment and management in India: a systematic review of interventional studies. Trans R Soc Trop Med Hyg. 2022;116(12):1101\u201311.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"3765_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/hpm.3081","volume":"36","author":"K Geethakumari","year":"2021","unstructured":"Geethakumari K, Kusuma YS, Babu BV. Beyond the screening: the need for health systems intervention for prevention and management of sickle cell disease among tribal population of India. Int J Health Plann Manage. 2021;36(2):236\u201343.","journal-title":"Int J Health Plann Manage"},{"issue":"3","key":"3765_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12687-022-00578-z","volume":"13","author":"BV Babu","year":"2022","unstructured":"Babu BV, Sridevi P, Surti SB, Ranjit M, Bhat D, Sarmah J, et al. Peripheral health workers\u2019 knowledge and experience related to sickle cell disease: an in-depth interview study in six tribal-dominated districts of India. J Community Genet. 2022;13(3):329\u201338.","journal-title":"J Community Genet"},{"issue":"7","key":"3765_CR17","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.4103\/jfmpc.jfmpc_2407_21","volume":"11","author":"A Bijlwan","year":"2022","unstructured":"Bijlwan A, Kumar S. Madhya Pradesh sickle cell mission: an initiative for screening, counseling and treatment of sickle cell disorders among tribal communities. J Family Med Prim Care. 2022;11(7):4101\u20132.","journal-title":"J Family Med Prim Care"},{"issue":"3","key":"3765_CR18","doi-asserted-by":"publisher","first-page":"e28875","DOI":"10.1002\/pbc.28875","volume":"68","author":"V Sheshadri","year":"2021","unstructured":"Sheshadri V, Shabeer P, Santhirapala V, Jayaram A, Krishnamurti L, Menon N. Mortality in sickle cell disease: A population-based study in an aboriginal community in the Gudalur Valley, Nilgiris, Tamil Nadu, India. Pediatr Blood Cancer. 2021;68(3):e28875.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"3765_CR19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.6026\/97320630014408","volume":"14","author":"I Das","year":"2018","unstructured":"Das I, Mishra H, Khodiar PK, Patra PK. Identification of therapeutic targets for inflammation in sickle cell disease (SCD) among Indian patients using gene expression data analysis. Bioinformation. 2018;14(7):408\u201313.","journal-title":"Bioinformation"},{"key":"3765_CR20","doi-asserted-by":"crossref","unstructured":"Dave K, Chinnakali P, Thekkur P, Desai S, Vora C, Desai G. Attrition from care and clinical outcomes in a cohort of sickle cell disease patients in a tribal area of Western India. Trop Med Infect Dis. 2019;4(4).","DOI":"10.3390\/tropicalmed4040125"},{"key":"3765_CR21","doi-asserted-by":"crossref","unstructured":"Raman V, Seshadri T, Joice SV. P NS. Sickle cell disease in India: a scoping review from a health systems perspective to identify an agenda for research and action. BMJ Glob Health. 2021;6(2).","DOI":"10.1136\/bmjgh-2020-004322"},{"issue":"6","key":"3765_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.4103\/ijmr.ijmr_1045_23","volume":"157","author":"RR Kishore","year":"2023","unstructured":"Kishore RR, Gupta M, Gupta K. A new era dawns on sickle cell disease in India. Indian J Med Res. 2023;157(6):491\u20133.","journal-title":"Indian J Med Res"},{"issue":"4","key":"3765_CR23","first-page":"441","volume":"115","author":"A Das","year":"2023","unstructured":"Das A, Dixit S, Kumar Barik M, Ghosal J, Babu B, Bal M, et al. Knowledge and perception related to sickle cell disease among tribal community, India: A mixed-method study. J Natl Med Assoc. 2023;115(4):441\u201353.","journal-title":"J Natl Med Assoc"},{"issue":"1","key":"3765_CR24","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/ijlh.12926","volume":"41","author":"JZ Xu","year":"2019","unstructured":"Xu JZ, Riolueang S, Glomglao W, Tachavanich K, Suksangpleng T, Ekwattanakit S, et al. The origin of sickle cell disease in Thailand. Int J Lab Hematol. 2019;41(1):e13\u20136.","journal-title":"Int J Lab Hematol"},{"key":"3765_CR25","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2023-177655","volume":"142","author":"W Jastaniah","year":"2023","unstructured":"Jastaniah W, Hartfield R, James J, Tinga B, lngoli E, de Montalembert M, et al. Sickle cell health awareness, perspectives, and experiences (SHAPE) survey: findings on the burden of sickle cell disease and impact on the quality of life of patients and caregivers in Gulf Cooperation Council countries. Blood. 2023;142:2516.","journal-title":"Blood"},{"key":"3765_CR26","doi-asserted-by":"crossref","unstructured":"de Montalembert M, Anderson A, Costa FF, Inusa BPD, Jastaniah W, Kunz JB et al. Sickle cell health awareness, perspectives, and experiences (SHAPE) survey: perspectives of adolescent and adult patients, caregivers, and healthcare professionals on the burden of sickle cell disease. Eur J Haematol. 2024.","DOI":"10.1111\/ejh.14211"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03765-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03765-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03765-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:21:07Z","timestamp":1748938867000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03765-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3765"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03765-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Roy Gomez is an employee and stockholder of Pfizer. Annabel Su is an employee of Ispsos UK and has no further conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}